Prediction of malignant behavior of pheochromocytomas and paragangliomas using immunohistochemical techniques

被引:39
作者
Kumaki, N
Kajiwara, H
Kameyama, K
DeLellis, RA
Asa, SL
Osamura, RY
Takami, H
机构
[1] Tokai Univ, Sch Med, Dept Pathol, Isehara, Kanagawa 2591163, Japan
[2] Teikyo Univ, Sch Med, Dept Surg, Tokyo 173, Japan
[3] Univ Toronto, Dept Pathol, Toronto, ON, Canada
[4] Brown Univ, Rhode Isl Hosp, Dept Pathol, Rhode Isl, MA USA
[5] Keio Univ, Sch Med, Dept Pathol, Tokyo 160, Japan
关键词
pheochromocytoma; paraganglioma; immunohistochemistry; MIB-1; S-100; protein; neuroenclocrine marker;
D O I
10.1385/EP:13:2:149
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Pheochromocytomas and paragangliomas arise from the adrenal glands and extraadrenal paraganglia, respectively. Malignant behavior of these tumors is uncommon and is, in part, dependent on their sites of origin, such as extraadrenal location. Morphologic criteria for malignancy of pheochromocytoma and paragangliomas have not been clearly defined. In this study, to clarify the histologic features that distinguish the benign from malignant pheochromocytomas and paragangliomas, we examined metastatic and nonmetastatic tumors using immunohistochemical techniques. A total of eight cases, five pheochromocytomas from the adrenal glands (four benign and one malignant tumor) and three paragangliomas with invasion or metastasis, were studied. The markers used in this study were chromogranin A, synaptophysin, NCAM (CD56), SNAP25, neuron-specific enolase, S-100 protein, and MIBA Our results suggest that MIB-1 immunostaining is a useful adjunct marker to predict malignant behavior in these tumors.
引用
收藏
页码:149 / 156
页数:8
相关论文
共 24 条
[1]   MALIGNANT PARAGANGLIOMAS OF THE HEAD AND NECK - CLINICAL AND IMMUNOHISTO-CHEMICAL CHARACTERIZATION [J].
BHANSALI, SA ;
BOJRAB, DI ;
ZARBO, RJ .
OTOLARYNGOLOGY-HEAD AND NECK SURGERY, 1991, 104 (01) :132-132
[2]  
Brown HM, 1999, CANCER, V86, P1583, DOI 10.1002/(SICI)1097-0142(19991015)86:8<1583::AID-CNCR28>3.0.CO
[3]  
2-#
[4]   Expression and prognostic value of c-erbB-2 oncogene product in human phaeochromocytomas [J].
CastillaGuerra, L ;
Moreno, AM ;
FernandezMoreno, MC ;
Utrilla, JC ;
Fernandez, E ;
GaleraDavison, H .
HISTOPATHOLOGY, 1997, 31 (02) :144-149
[5]   Prognostic markers in pheochromocytoma [J].
Clarke, MR ;
Weyant, RJ ;
Watson, CG ;
Carty, SE .
HUMAN PATHOLOGY, 1998, 29 (05) :522-526
[6]  
de Krijger RR, 1999, J PATHOL, V188, P51
[7]  
GROUZMANN E, 1990, CANCER, V66, P1833, DOI 10.1002/1097-0142(19901015)66:8<1833::AID-CNCR2820660831>3.0.CO
[8]  
2-9
[9]   Prognostic value of immunohistochemical expression of topoisomerase alpha II, MTB-1, p53,E-cadherin, retinoblastoma gene protein product, and HER-2/neu in adrenal and extra-adrenal pheochromocytomas [J].
Gupta, D ;
Shidham, V ;
Holden, J ;
Layfield, L .
APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY, 2000, 8 (04) :267-274
[10]   Pheochromocytomas: Can malignant potential be predicted? [J].
John, H ;
Ziegler, WH ;
Hauri, D ;
Jaeger, P .
UROLOGY, 1999, 53 (04) :679-683